Thermo Fisher CEO Marc Casper sells $8.6m in TMO stock By Investing.com

Marc N. Casper, Chairman and CEO of Thermo Fisher Scientific Inc. (), sold company stock worth approximately $8.6 million on August 6, 2026. The transactions also included the acquisition of shares through the exercise of stock options. The stock has delivered a strong 31% return over the past year, and currently trades at $593.88, above Casper’s sale prices. According to InvestingPro analysis, the stock appears overvalued at current levels.

Mr. Casper disposed of a total of 15,000 shares of Thermo Fisher common stock. These sales occurred at prices ranging from $571.0 to $580.01 per share. Of the total, 10,000 shares were sold directly, while an additional 5,000 shares were sold indirectly by Floral Park Associates, Inc. All sales were conducted under a Rule 10b5-1 trading plan, which Mr. Casper adopted on April 27, 2026.

Concurrently, Mr. Casper acquired 10,000 shares of common stock by exercising stock options at a price of $309.63 per share, totaling approximately $3.1 million. The options, which represent a right to buy shares, vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.

Following these transactions, Mr. Casper directly owns 123,925.358 shares and indirectly owns 4,608 shares through Floral Park Associates, Inc. Thermo Fisher, with a market cap of $218 billion, is a prominent player in the Life Sciences Tools & Services industry. For deeper insights into TMO’s valuation and financial health, investors can access the comprehensive Pro Research Report available on InvestingPro, covering this and 1,400+ other US equities.

In other recent news, Thermo Fisher Scientific reported its second-quarter 2026 results, surpassing expectations with adjusted earnings of $6.03 per share and revenue of $11.99 billion. These figures exceeded Wall Street’s projections of $5.72 per share and $11.71 billion in sales. The company also raised its full-year outlook, attributing the positive adjustment to increased customer activity across its end markets. Revenue for the quarter rose by 10% compared to the previous year, with organic revenue growth at 5%. Additionally, Thermo Fisher’s adjusted operating margin improved to 22.8%, up from 21.9% a year earlier. Management highlighted stronger demand in the pharma and biotech sectors, as well as favorable conditions in academic and government markets. The company also noted solid contributions from recent acquisitions. These developments reflect a broad-based improvement in Thermo Fisher’s business performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.